🇺🇸 FDA
Patent

US 10301371

Cyclic monomer and dimer peptides having integrin antagonist activity

granted A61KA61K38/00A61K47/542

Quick answer

US patent 10301371 (Cyclic monomer and dimer peptides having integrin antagonist activity) held by Protagonist Therapeutics, Inc. expires Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Protagonist Therapeutics, Inc.
Grant date
Tue May 28 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K38/00, A61K47/542, A61K47/545, A61K47/60